SCHEMBL5111737

SCHEMBL5111737

CC1(C)CN(c2cc(F)ccc2N2CCC(NC(=O)C3(NC(=O)c4ccco4)CCCCC3)C(O)C2)C1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 6/20 0.33
NPSR1 Q6W5P4 3/20 0.33
HSD17B10 Q99714 3/20 0.33
HPGD P15428 3/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 3/20 0.33
THRB P10828 1/20 0.33
ADRA1D P25100 2/20 0.32
ADRA1A P35348 2/20 0.32
ADRA1B P35368 2/20 0.32
KDM4E B2RXH2 3/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
CREBBP Q92793 1/20 0.32
PKM P14618 1/20 0.32
ACKR3 P25106 1/20 0.31
XBP1 P17861 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5098552 0.87 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5098243 0.87 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5105158 0.86 CTSL (0.34) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5105424 0.85 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5097938 0.83 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5101583 0.82 ALDH1A1 (0.34) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5101585 0.82 MAPT (0.35) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5105626 0.81 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5111723 0.80 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD
SCHEMBL5104866 0.80 ALDH1A1 (0.35) SMN1; SMN2ALDH1A1NPSR1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342027-B2 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2008-03-11 US disclosed
US-20050234057-A1 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof DONG-A PHARMACEUTICAL CO., LTD. (KR) 2005-10-20 US disclosed
WO-2004011457-A1 1-PHENYLPIPERIDIN-3-ONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234057-A1 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof CTRL, PRCP, CLPP SMN1; SMN2 4244/4885ALDH1A1 740/4885NPSR1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.